secwatch.observer — SEC 8-K summary
======================================

Issuer:     CEL SCI CORP (CVM)
CIK:        0000725363
Form:       8-K
Filed at:   2023-10-24T23:59:59+00:00
Accession:  0001654954-23-013323
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEL-SCI's Multikine shows 28% absolute 5-year survival benefit in head & neck cancer target population at ESMO
--------------------------------------------------------------------------------

- Target population: low PD-L1 (<10%), N0, no extracapsular spread; covers ~145,000 patients/year worldwide.
- 5-year survival 73% with Multikine vs 45% control (p=0.0015); hazard ratio 0.35, 65% risk reduction.
- Pre-surgery disease downstaging observed in 35% of Multikine patients; linked to improved survival.
- Pre-application regulatory filings submitted in UK and Europe; plans to file in US and Canada for immediate approval without confirmatory study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/725363/000165495423013323/0001654954-23-013323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/725363/000165495423013323/cvm_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-013323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer